Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 1;36(7):1053-1054.
doi: 10.1097/QAD.0000000000003221.

Weight gain stopping/switch rules for antiretroviral clinical trials

Vinie Kouamou  1 , Seth Inzaule  2 , Justen Manasa  1
Affiliations
Comment

Weight gain stopping/switch rules for antiretroviral clinical trials

Vinie Kouamou et al. AIDS. .
No abstract available

PubMed Disclaimer

Comment on

  • Weight gain stopping/switch rules for antiretroviral clinical trials.
    Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Sekwese K, Mashabane N, Pozniak A, Khoo S, Ali M, Delaporte E, Lalla-Edwards S, Clayden P, Marconi VC, Siedner MJ, Boffito M, Serenata C, Carman M, Collins S. Venter WDF, et al. AIDS. 2021 Dec 15;35(Suppl 2):S183-S188. doi: 10.1097/QAD.0000000000003092. AIDS. 2021. PMID: 34848585 Free PMC article.

References

    1. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV; 2018. https://www.who.int/publications-detail-redirect/WHO-CDS-HIV-18.51
    1. Clinton Health Access Initiative. The state of HIV treatment, testing, and prevention in low- and middle-income countries. Issue 12, October 2021. https://www.clintonhealthaccess.org
    1. Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, et al. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study . PLoS One 2020; 15:e0232419.
    1. Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy . Clin Infect Dis 2020; 70:1267–1274.
    1. Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials . Clin Infect Dis 2020; 71:1379–1389.

Substances